| 2025年度 |
LOGIK |
LOGIK2102 |
Atezolizumab with carboplatin plus nab-paclitaxel
combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: a multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102) |
European Journal of Cancer |
DOI ↗
|
九州大学
白石 祥理 |
| 2025年度 |
その他 |
肺の生活習慣病コホート研究 |
Prognostic impact of muscle mass in idiopathic interstitial pneumonia: analysis of idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias |
BMC Pulmonary Medicine |
DOI ↗
|
九州大学
萩原 拓貴 |
| 2025年度 |
W-JHS |
W-JHS AA01 |
Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study |
British Journal of Haematology |
DOI ↗
|
国立国際医療センター
石山 謙 |
| 2025年度 |
その他 |
肺の生活習慣病 コホート研究 |
Association between single nucleotide polymorphisms and disease susceptibility, survival, and acute exacerbation in idiopathic pulmonary fibrosis |
Respirology |
DOI ↗
|
九州大学
坪内 和哉 |
| 2025年度 |
LOGIK |
LOGIK2001 |
Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED) |
ESMO Open 2025; 10: 105325. |
DOI ↗
|
九州大学
白石 祥理 |
| 2025年度 |
LOGIK |
LOGIK0902/ OLCSG0905 |
Retreatment With EGFR-Tyrosine Kinase
Inhibitor After Disease Progression Following
Gefitinib Induction and Chemoradiotherapy in
EGFR-Mutant Stage III Non-small Lung Cancer:
An Efficacy and Safety Analysis of the
LOGIK0902/OLCSG0905 Study |
Cureus 17(6): e86575. |
DOI ↗
|
熊本中央病院
佐伯 祥 |
| 2025年度 |
その他 |
J-FOCAL |
Multicenter cohort study of the effect of Crinone® progesterone vaginal gel alone to prepare the endometrium for frozen–thawed blastocyst transfer in a hormone replacement cycle |
Journal of Obstetrics and Gynaecology Research
2025; 51, e16325 |
DOI ↗
|
東邦大学医療センター佐倉病院
高島 明子 |
| 2025年度 |
LOGIK |
LOGIK2003 |
Turtle study: A phase II study of durvalumab plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancer (LOGIK 2003) |
JTO Clinical and Research Reports |
DOI ↗
|
久留米大学
石井 秀宣 |
| 2025年度 |
LOGIK |
LOGIK2002 |
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal
function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002) |
Lung Cancer 203 (2025) 108543 |
DOI ↗
|
九州大学
白石 祥理 |
| 2024年度 |
LOGIK |
LOGIK0902/ OLCSG0905 |
Five-Year Outcomes with Gefitinib Induction and Chemoradiotherapy in EGFR-Mutant
Stage III Non-Small-Cell Lung Cancer: LOGIK0902/OLCSG0905 Phase II Study |
International Journal of Clinical Oncology |
DOI ↗
|
岡山大学
堀田 勝幸 |
| 2024年度 |
その他 |
BIO-NEXT |
Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study) |
Frontiers in Immunology |
DOI ↗
|
九州がんセンター
佐藤 晋彰 |
| 2024年度 |
その他 |
肺の生活習慣病コホート研究 |
Update of prognosis and characteristics of chronic obstructive pulmonary disease in a real-world setting: a 5-year follow-up analysis of a multi-institutional registry |
BMC Pulmonary Medicine |
DOI ↗
|
九州大学
髙野 智嗣 |
| 2024年度 |
LOGIK |
LOGIK2004 |
Nivolumab plus Ipilimumab with Chemotherapy for Non–Small Cell Lung Cancer with Untreated Brain Metastases: A Nonrandomized Controlled Phase 2 Trial(NIke, LOGiK 2004) |
European Journal of Cancer |
DOI ↗
|
北九州市立医療センター
土屋 裕子 |
| 2024年度 |
LOGIK |
LOGIK1902 |
A phase II study of weekly carboplatin and concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer (LOGIK1902) |
Thoracic Cancer |
DOI ↗
|
JCHO九州病院
原田 大志 |
| 2024年度 |
その他 |
Cryo-tsc |
Safety and Efficacy of Cryotherapy for the Treatment of Renal Angiomyolipoma Related to Tuberous Sclerosis Complex: The Cryo-TSC Study |
JU Open Plus
2(6):e00051, June 2024. |
DOI ↗
|
九州大学
柏木 英史 |